Abstract: Type 1 diabetes mellitus (T1DM) is associated with several skeletal alterations, particularly in conditions of poor glycaemic control. Insulin therapy is the major conservative treatment for T1DM; however, the effects of this hormone on bone markers of T1DM rats are limited, and the regulatory mechanisms remain elusive. Therefore, the evaluation of molecular and non-molecular parameters in a chronic animal model of T1DM-induced bone loss, treated with and without insulin, may help in elucidating the insulin mechanisms. Male Wistar rats were assigned into three groups: control, T1DM (T1DM rats induced with streptozotocin [STZ] at 40 mg/kg intravenously) and T1DM plus insulin therapy (T1DMI). After 8 weeks, we evaluated the serum biochemical, tibia histomorphometric and biomechanical parameters, as well as the gene expression of the receptor activator of nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG) and osteocalcin (OC) of femur mRNA. Compared with T1DM, the T1DMI group showed less bone loss, which was revealed by the increased trabecular width (TbWi, p < 0.001) and trabecular bone area (BAr, p < 0.01), reduced trabecular separation (TbSp, p < 0.01) and increased Young's modulus (p < 0.05). Moreover, molecular analyses indicated that the expression of OPG and OC was up-regulated (p < 0.001 and p < 0.05, respectively). In summary, the up-regulation of OPG and OC in the T1DMI group supports an anabolic effect of insulin, which was demonstrated by the maintenance of bone architecture and flexibility. These results suggest that insulin therapy may prevent T1DM-induced bone loss via the effects on the bone formation.
Type 1 diabetes mellitus (T1DM) is a systemic metabolic disease characterized by chronic hyperglycaemia and is triggered by insulin deficiency [1] . Low insulin levels in T1DM are associated with a variety of skeletal disorders, including reduced bone mineral density, altered bone metabolism and osteopenia and/or osteoporosis [2, 3] .
These skeletal disorders are due to an imbalance between bone formation and resorption [3, 4] . In recent reviews, investigators have proposed that diabetes decreases the osteoblast function by changing several bone formation markers, including osteocalcin (OC) and osteoprotegerin (OPG), leading to the accelerated bone loss, osteopenia and osteoporosis [5, 6] . OPG is a member of the RANK/RANKL/OPG system, which is known to have a major role in bone turnover [7] , and OC is an osteoblast-specific protein directly associated with the regulation of extracellular matrix mineralization and is secreted into the general circulation by the osteoblastic cells [8, 9] .
It is of interest that the alterations in these markers were previously observed by our study group in children and adolescents with early-onset T1DM, and T1DM patients with low bone mineral density had an increased expression of OPG mRNA in leucocytes and low serum concentrations of OC [2] .
On the other hand, a growing body of evidence suggests that bone protection is due to the anabolic effects of insulin in both diabetic animal models and human beings [6, 10, 11] . The improvements of insulin therapy include the increased bone density and strength, probably via the direct and/or indirect effects on bone formation [12] . However, the mechanisms involved in the effects of insulin therapy on these molecular markers are poorly understood.
Therefore, this study aimed to evaluate the effects of insulin therapy on bone tissue via the analysis of mRNA expression of RANKL, OPG and OC in a chronic animal model of T1DM induced with STZ. In addition, we evaluated the serum biochemical as well as bone histomorphometric and biomechanical parameters. 
Materials and Methods
Experimental protocol. All animal experiments and protocols were approved by the Institutional Animal Research Ethics Committee (under Protocol No. 022/2009). All procedures were carried out in strict accordance with the recommendations from the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health [13] .
Fifteen male Wistar rats (weight 220 AE 20 g) were obtained from the animal care facility of the Federal University of Rio Grande do Norte, Brazil. The animals were housed in standard conditions (12-hr light/dark cycle, temperature of 22-24°C and relative humidity of 50-60%), with food and water ad libitum provided during the entire experimental period. After 1 week of acclimatization before the experimental procedures, the animals were randomly assigned and equally distributed (five rats per group) into the following groups: control group, T1DM group and T1DM plus insulin therapy group (T1DMI). The diabetic groups initially had a larger sample size (12 animals per group). However, owing to a high mortality rate among the rats (above 60%), the final sample size was five animals per group.
Experimental diabetes was induced via a single intravenous injection of streptozotocin (STZ, Sigma-Aldrich, St. Louis, MO, USA) dissolved in freshly prepared sodium citrate buffer (0.1 M, pH 4.5) at a dose of 40 mg/kg of body-weight [14] . Equal volumes of vehicle were injected into the control rats. On the fifth day after the induction, the blood samples were collected by tail bleeding and glycaemia was assayed using an Accu-Chek â Advantage glucometer (Roche Diagnostics, Indianapolis, IN, USA). The blood glucose concentration and body-weight were monitored fortnightly for a period of 8 weeks. Symptoms of clinical diabetes such as polyphagia, polydipsia, polyuria and body-weight loss were also monitored. Animals with blood glucose concentrations ≥ 250 mg/ dL were considered diabetic.
One day after the confirmation of diabetes, the animals from the T1DMI group received daily subcutaneous doses of neutral protamine Hagedorn insulin (Humulin U-100, 100 U/mL, Eli Lilly, São Paulo, Brazil) diluted in 0.9% NaCl (2.5 IU twice a day, at 7 a.m. and 7 p.m.). The animals in the control and T1DM groups received only saline by the same route during the study. The insulin doses were standardized under the same conditions as the pilot study. The standardization was performed over a period of 30 days, and the protocol was chosen after the careful evaluation of the glucose concentrations, which were measured throughout the day. The twice-daily 2.5-IU insulin dose, outlined in the protocol, had no impact on animal mortality, allowed for a better maintenance of glucose concentration and showed results similar to the control group.
Blood and tissue collection and routine biochemical analyses. Fasting animals were killed using a lethal dose of thiopental (100 mg/kg). To prevent the possible daily cyclic variations in data, all animals were killed between 7:00 a.m. and 9:00 a.m., after a subcutaneous dose of insulin (2.5 IU). Blood samples were obtained from the abdominal aorta and bone tissues were harvested and stored for the subsequent total RNA extraction (right femurs) as well as for the histomorphometric (right tibia) and biomechanical (left tibia) analyses.
Serum glucose, total calcium, phosphorus concentration and alkaline phosphatase (ALP) activities were determined using the routine methods (BioSystems Reagents and Instruments, Barcelona, Spain) and using an RA 50 spectrophotometer (Chemistry System, Bayer Diagnostic, Dublin, Ireland) in triplicate. Serum ionized calcium was measured using the AVL 9180 Electrolyte Analyser (Roche, Roswell, GA, USA). The pre-analytical errors, especially in the measurement of ionized calcium, were minimized by the appropriate fasting of the animals, the use of serum and the use of serum separator collection tubes containing gel (BD Diagnostics, Franklin Lakes, NJ, USA) [15] .
Histological preparation and histomorphometric analyses. Histology was performed according to Duarte et al. Briefly, the right tibia of each animal was fixed in a 10% buffered formalin solution, decalcified in 7.5% nitric acid, processed and embedded in paraffin. Longitudinal 7-lm sections were stained with haematoxylin and eosin. The histomorphometric results represent the means of four measurements of trabecular separation (TbSp, lm), trabecular width (TbWi, lm) and trabecular bone area (BAr, %) obtained from the metadiaphyseal region by using a Nikon Labophot microscope equipped with a 109 magnification ocular lens (Nikon, Tokyo, Japan). The analyses were performed using ImageJ â software version 1.48v (National Institutes of Health, Bethesda, MD, USA), and data were reported in lm. All parameters were compiled according to the guidelines of the Nomenclature Committee of the American Society of Bone and Mineral Research [16] .
Biomechanical analysis. Biomechanical analysis was performed in left tibia tissue that was previously stored at À80°C for three-point bending mechanical tests [14] . We used a servo-hydraulic highprecision universal testing machine, model AG-X 10 kN (Shimadzu Corporation, Tokyo, Japan). Left tibia samples were placed horizontally on a frame with rounded edges at a distance of 30 mm.
The load was applied at the mid-shaft of the diaphysis by using a punch with a rounded notch. The rate of the imposed displacement was selected at 5 mm/min to simulate the static loading conditions. Displacement was imposed continuously until fracture. Failure in the load-displacement curves was defined and observed by the propagation of a nearly vertical fracture starting almost universally at the lower cortical bone surface. Ultimate load (N), stiffness (N/mm), ultimate stress (N/mm 2 ), ultimate strain (%) and Young's modulus (GPa) were recorded.
RNA extraction and reverse transcriptase quantitative polymerase chain reaction (RT-qPCR). The right femur of each animal, previously stored at À80°C, was pulverized, and the total RNA was extracted using RNeasy Plus Mini Kit (Qiagen, Valencia, CA, USA). RNA integrity was assessed by electrophoresis in 1.0% agarose gels with MOPS [3-(N-morpholino)propanesulfonic acid] buffer, and RNA was quantitated using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and stored at À80°C. cDNA was synthesized using 1 lg of total RNA and the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's protocol, in a MyCycler thermal cycler (Bio-Rad, Philadelphia, PA, USA). cDNA was obtained in a final volume of 50 lL and stored at À20°C for later use in the RT-qPCR expression assays.
RT-qPCR was performed using the TaqMan assay with the genes RANKL (Rn00589289_m1), OPG (Rn00563499_m1), OC (Rn00566386_g1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Rn00579162_m1) (Applied Biosystems). GAPDH was used as the reference gene. PCR assays were carried out in 96-well plates using a 7500 Fast Real-Time PCR System (Applied Biosystems). Relative expression was calculated using the 2 ÀDDCT method [17] , and the results were presented as fold change versus the mean values of the control group, normalized to GAPDH, for which C t did not show significant variations between the control and T1DM groups. All molecular tests were performed according to the procedures described by Bortolin et al.
Statistical analyses. Statistical analyses were performed with GraphPad PRISM software version 5.0 (GraphPad Software Inc., San Diego, CA, USA). For all data, the normality test failed (Kolmogorov-Smirnov), and for this reason, we used the nonparametric Kruskal-Wallis and Dunn's post hoc method of multiple comparisons versus the control. Spearman's linear correlation was used to determine the relationship between serum glucose level and other variables; p values of less than 0.05 were considered statistically significant.
Results

Biochemical analysis and body-weight.
The serum biochemical analysis and body-weight data are listed in table 1. As expected, at the end of the experimental period, body-weight was significantly lower (p < 0.01) in the T1DM group compared with the control group. On the other hand, the body-weight of T1DMI animals was similar to that of the control animals.
The T1DM group showed higher levels of blood glucose than the control rats (p < 0.01). In addition to hyperglycaemia, we observed polyphagia, polydipsia and polyuria (data not shown) in diabetic rats, indicating that the experimental STZinduced T1DM model was successful. In contrast, insulin therapy decreased the blood glucose levels in the T1DMI animals compared with the T1DM group (p < 0.01).
With respect to serum biochemical markers, the calcium levels were higher in both diabetic groups (p < 0.05) compared with the control group; however, the levels in the T1DMI group were higher than those in the T1DM group (p < 0.01) (table 1). Serum ionized calcium concentrations were significantly lower in the T1DMI group than in the control group (p < 0.01). No differences in serum phosphorus concentrations were found between the studied groups.
Serum ALP activity was higher in the T1DM group as compared to the activity in both T1DMI and control groups (p < 0.01); however, the ALP activity in the T1DMI group was lower than in the T1DM group (p < 0.01).
Histological and histomorphometric analyses of the bone. Figs 1 and 2 show the histological and histomorphometric data, respectively. Significant differences in histological ( fig. 1A-C ) and histomorphometric data ( fig. 2A-C) were found between the T1DM and T1DMI groups. In particular, the T1DMI group showed higher TbWi (p < 0.001) and BAr (p < 0.01) and lower TbSp (p < 0.01) than the T1DM group. By contrast, the T1DM group exhibited higher TbSp ( fig. 2A ) and lower TbWi ( fig. 2B ) and BAr ( fig. 2C ) compared with the control group (p < 0.001 and p < 0.01, respectively). In addition, there was a positive correlation between glycaemia and TbSp (p < 0.01; R = 0.68) and there was a negative correlation between glycaemia and BAr (p < 0.01; R = À0.80) in the T1DM group. RANKL, OPG and OC mRNA expression data.
Gene expression data are shown in fig. 3 . Although there were no significant differences in mRNA expression of RANKL between the groups tested ( fig. 3A) , the T1DMI group showed a 3 times higher level of RANKL expression compared with T1DM. By contrast, the T1DM group exhibited a 2 times lower RANKL expression compared with the control group. The mRNA expression levels of OPG increased approximately 2 times in the T1DMI group compared with T1DM (p < 0.001) and increased 1.8 times compared with the control group ( fig. 3B ). In addition, the mRNA expression levels of OC increased 1.2 times (p < 0.05) in the T1DMI group compared with the T1DM group ( fig. 3C ).
Discussion
Clinical and epidemiological studies have provided evidence for the link between T1DM, low bone mass and fractures [18] . Diabetic bone disease may be an overlooked complication of diabetes, in which bone markers and bone turnover are lower and may depend on the glycaemic control, duration of illness and presence of vascular complications caused by DM [6, 18] .
Despite the association between bone loss and low insulin levels in T1DM [6, 12] , the effects of insulin therapy on the pathogenesis of diabetes-related bone disorders are unclear, and its underlying mechanisms remain elusive [10, 19, 20] .
Controversies on the effect of insulin on T1DM bone have been reported [20, 21] and highlight the importance of understanding the effects of insulin on the bone metabolism. Erdal et al. suggested that insulin treatment might protect the mineral integrity of the bone against STZ-induced T1DM by suppressing the bone loss. However, they observed that insulin treatment failed to ameliorate the deteriorative effects of STZinduced T1DM on the collagen integrity and the geometric features, resulting in weaker, fragile and poor-quality bones [20] . In contrast, Mishima et al. [21] showed that the volume of the bone formed and the number of osteoclasts were significantly lower in diabetic rats than in the controls and that insulin treatment normalized these histomorphometric parameters of bone turnover.
The STZ-induced diabetes model has been extensively used and has provided invaluable insights into the pathogenesis of this disease [14, 20, 22, 23] . Indeed, the induction of diabetes with STZ in rats causes a bone phenotype consistent with that observed in human beings [2, 24, 25] and with that of spontaneous mouse models such as NOD mice [10, 26] . Moreover, the number of animals used in most of these studies varied between 5 to 12, confirming its utility for studying mechanisms of insulin therapy in T1DM-induced bone loss. In the present study, the success of STZ protocol was observed by high serum glucose concentration in diabetic animals on the fifth day after the induction, as well as by serum glucose ≥ 250 mg/dL associated with clinical diabetic symptoms such as polyphagia, polydipsia, polyuria and bodyweight loss at the end of the experimental period in T1DM rats. In addition, these results are in agreement with those of previous studies performed in our laboratory [14, 27] .
A significant reduction in glucose concentration was seen in the animals subjected to insulin therapy daily, confirming the success of the insulin protocol. The slight hypoglycaemia observed in the T1DMI rats may have resulted from fasting on the day of killing. Similar results were observed in a previous study on STZ-induced diabetes in the rats treated with insulin [19] . Aside from the glucose concentration, we believe that this protocol did not affect any of the other serum parameters evaluated.
In the present study, we used an STZ-induced T1DM model to evaluate the serum biochemical, tibia histomorphometric and biomechanical properties, and femur mRNA expression in animals with chronic hyperglycaemia (T1DM group) and/or those treated with insulin (T1DMI group) for 60 days.
The present histomorphometric results showed a protective effect of insulin therapy against T1DM-induced bone loss, which was demonstrated by the increased TbWi and BAr and decreased TbSp. Indeed, these values were similar to those of the control group, suggesting a beneficial effect of insulin on the maintenance of bone architecture. In contrast, the bone loss observed in the T1DM group, which did not receive insulin therapy, supports the anabolic effect of this hormone. In addition, a positive correlation between hyperglycaemia and TbSp and an inverse correlation between hyperglycaemia and BAr were observed in the T1DM group, reinforcing the previous results on the deleterious effects of high blood glucose on the bone tissue [10, 14, [27] [28] [29] .
Bone abnormalities in STZ-induced T1DM rats have been demonstrated in previous studies performed in our laboratory [14] as well as by other investigators [20, 29] , indicating that diabetes may reduce the bone strength by affecting the mineral composition and collagen integrity as well as via the direct effects of insulin deficiency and hyperglycaemia. Chronic hyperglycaemia directly suppresses the osteoblast-mediated bone formation and promotes the osteoclast-mediated bone resorption, adipogenic differentiation of mesenchymal stem cells and fat accumulation in the marrow cavity [5] . In addition to the negative effect of hyperglycaemia on the bone, the rapid and significant weight loss observed in the T1DM animals may also be associated with the increased bone loss due to T1DM. This hypothesis is supported by the previous studies, which indicated that body-weight is directly associated with bone mineral density (BMD) and identified a low body mass index (BMI) as an important risk factor for low BMD that predicts the age-related bone loss [30, 31] . Considering that all of these effects may contribute to bone deterioration and fragility, as well as may increase the risk of fracture [3, 5] , the preventive effect of insulin therapy on the weight loss and reduced serum glucose concentration, leading to the better metabolic control, could help protect against the significant bone loss caused by T1DM.
Interestingly, in our study, we found that the preventive effects of insulin therapy on bone were due to the inhibition of the reduction in the Young's modulus, which suggests that insulin could protect the bone against the collagen degradation. In addition, insulin therapy maintained the levels of other parameters such as stiffness, ultimate stress, ultimate strain and ultimate load, which are similar to those observed in the control group. These parameters are fundamental for evaluating the fragility and biomechanical integrity of the bone structure [32] and indicate the beneficial effects of insulin therapy on the maintenance of the mechanical properties of bones in diabetic rats, which are similar to those of the healthy rats. The results obtained from the biomechanical tests may be supported by the reduced concentration of ionized calcium observed in the sera of T1DMI rats, suggesting that the increased absorption of the active form of the ion may result in an improved bone quality.
In the present study, an increase in the total calcium ion concentration was also observed in the sera of all diabetic rats. However, it is important to highlight the fact that the maintenance of calcium homeostasis is critical and that there was no consensus regarding the serum calcium values in the literature, perhaps because the physiological control of calcium metabolism and skeletal remodelling is under the regulation of several systemic hormones, such as parathyroid hormone (PTH), 1,25- dihydroxyvitamin D (calcitriol) and calcitonin (CT) [33, 34] . Thus, serum calcium concentration is tightly regulated by the calcitrophic hormones and is often a poor marker of bone turnover [3] . Moreover, many other factors, such as metabolic acidosis in T1DM, are associated with an imbalance in calcium homeostasis. Studies have shown that metabolic acidosis can suppress the bone formation and increase the bone resorption by stimulating the activity of osteoclasts [35, 36] to dissolve hydroxyapatite for the calcium release from the bone. In addition, the diabetic rats had accentuated polydipsia and polyuria symptoms, which may also have contributed to an imbalance in the electrolyte levels in the bloodstream. Electrolyte disturbances are common in patients with diabetes, and dehydration might represent the most important causative factor for the occurrence of hypercalcemia in this case [37, 38] .
However, despite the lack of any change in the total calcium levels in serum, a beneficial effect of insulin therapy on polyuria and polydipsia symptoms and on bone mechanical properties was observed, likely resulting from the maintenance of bone structure, which may be associated with calcium metabolism among other factors. Additionally, better glucose control may bring about an improvement in acid-base homeostasis in these animals, which may reflect the better calcium deposition.
We also evaluated the activity of ALP, an important serum marker associated with the bone formation, the concentration of which is often increased in the case of bone disorders [3, 39] . Serum total ALP activity also includes other ALP from other cell types, namely liver and intestine [39] . Our results showed an increase in ALP activity in the T1DM group. According to Vestergaard [40] , no study has reported a significant decrease in ALP activity in patients with diabetes when compared with controls. One study reported a 7% non-significant decrease in both total ALP and bone-specific ALP [41] , while two other studies [42, 43] reported small non-significant decreases in the total ALP (2% and 4%, respectively). Alternatively, another study reported the increased levels of ALP in young adult patients with T1DM in whom hepatic and renal functions were similar in both groups, diabetic and control, thus concluding that this observation referred to the bone origin ALP [39] . Similarly, an increased ALP activity in rats with T1DM-induced bone loss was observed in previous studies performed in our laboratory [14, 27] and in a study performed by Botolin and McCabe [44] . These investigations demonstrated that the osteoblast response to chronic hyperglycaemia was induced by the activation of ALP and the suppression of OC, thus supporting our results. Recently, Joshi et al. [45] observed a negative association between ALP levels and BMD in patients with T1DM.
This imbalance appears to be a characteristic of the bone complication of T1DM and reflects an impairment in osteoblast differentiation and maturation. During the development, osteoblasts undergo a series of differentiation stages, such as proliferation, matrix development and matrix mineralization [39] . Bone-specific ALP activity is expressed early during the development of osteoblasts, is at maximum during the phase of matrix maturation and is down-regulated during the late stages of matrix mineralization [46] . These findings are supported by an in vitro study that observed a significantly higher level of ALP in the cells incubated in the presence of high glucose concentration. At the end of the experimental period, the total amount of calcium uptake into the glucose-treated cells was almost half of that in the control cells; in other words, it took significantly longer to deposit the same amount of calcium [47] .
Therefore, the increased ALP activity in the T1DM group is probably a response to the hyperglycaemic state, and it might be an attempt to restore the bone metabolism, suggesting an impairment in osteoblast differentiation and maturation, which inhibited the later stages of matrix mineralization. Our hypothesis is supported by the observation of poor bone biomechanics and architecture in T1DM rats. However, a significant reduction in ALP activity by insulin therapy may indicate the beneficial effects of the hormone on the bone metabolism, which was supported by the maintenance of bone architecture and mechanics similar to those in control animals.
Furthermore, we performed the molecular analysis of RANKL, OPG and OC mRNA expression. Compared with the T1DM group, OPG and OC mRNAs were up-regulated in the animals treated with insulin, suggesting that insulin has a significant anabolic and protective effect on osteoblasts, and this up-regulation may lead to the increased protein synthesis and the suppression of diabetes-induced bone loss. In addition, to the best of our knowledge, this is the first study that reported the increased mRNA expression of OPG in the bone tissue in a chronic model of diabetes-induced bone loss treated with insulin.
OPG is expressed primarily via the positive regulation of bone marrow stromal cells by several factors such as tumour growth factor-b, interleukin-1, tumour necrosis factor, oestrogen and Wnt ligands, and it is negatively regulated by prostaglandin E2 [48] . In the bone, OPG is believed to function primarily as a decoy receptor to modulate the interactions between ligands and signalling receptors by binding to RANKL and consequently decreasing bone-resorbing and maintaining bone homeostasis [48] . The increased expression of OPG may lead to the prevention of bone loss by binding directly to RANKL, therefore blocking RANK receptor signalling in preosteoclasts. These regulation mechanisms would consequently decrease the osteoclast multiplication and survival and bone resorption [48] .
The peptide OC positively regulates osteogenesis and is a biomarker of bone formation; it is primarily expressed in postproliferating and terminally mature osteoblasts and promotes the regulation of bone extracellular matrix [8, 49] . In diabetes, the production of this peptide is impaired by the negative regulation of osteoblasts via the decreased synthesis of insulin, amylin and preptin [49] , supporting the anabolic effects of insulin therapy observed in the present study.
Furthermore, the up-regulation of OPG and OC mRNA is supported by the biomechanical and histomorphometric parameters, suggesting that these genes may contribute to the maintenance of the architecture, strength and flexibility of the diabetic bone, under the effect of insulin therapy.
The major limitations of the present study are the use of animal models and the small sample size; however, the STZinduced T1DM model has been used by several investigators to evaluate the pathophysiology of osteoporosis and the effect of therapeutic interventions against the bone loss induced by T1DM [14, 20, 22, 23, 27] . In addition, this animal model of diabetes has increased our understanding of the fundamental mechanisms underpinning T1DM-induced bone loss and has recently contributed to several major advances in treatment.
We have to consider that only a few investigators have attempted to evaluate the action of insulin on the mRNA expression of osteoblast-specific genes such as OC and OPG in animal models and human beings. Therefore, our results may help elucidate the relationship between insulin and bone turnover in T1DM.
In summary, our results indicated a protective and osteoanabolic effect of insulin therapy, and this effect may be associated with the up-regulation of OPG and OC in the osteoblasts, leading to the maintenance of the mineral structure and collagen integrity in the T1DMI group and consequently contributing to the maintenance of bone architecture and flexibility. Moreover, the present results add valuable information for the mechanisms underlying the protective effects of insulin in T1DM-induced bone loss.
